HYTRIN
LOE ApproachingNDAORALTABLET
Approved
Aug 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYTRIN is an oral small-molecule tablet approved in 1987 by Abbott for an undisclosed indication(s). The specific mechanism of action and therapeutic area remain unknown from available data, limiting detailed clinical characterization.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams are likely focused on lifecycle extension or managed decline strategies, indicating reduced hiring and consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Started Aug 1998
1,993 enrolled
Prostatic Hyperplasia
Career Relevance
HYTRIN presents limited career growth opportunities due to its LOE-approaching lifecycle stage and zero linked job openings. Roles available are primarily defensive—protecting market share, managing generic transition, and ensuring compliance—rather than driving innovation or expansion.
Brand Manager
Worked on HYTRIN at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.